BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9531295)

  • 1. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes.
    Siebenkotten IM; Carstens C; Koch N
    J Immunol; 1998 Apr; 160(7):3355-62. PubMed ID: 9531295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel domain on HLA-DRbeta chain regulates the chaperone role of the invariant chain.
    Neumann J; Koch N
    J Cell Sci; 2006 Oct; 119(Pt 20):4207-14. PubMed ID: 16984974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of glycosylation of MHC class II-associated invariant chain by translocon-associated RAMP4.
    Schröder K; Martoglio B; Hofmann M; Hölscher C; Hartmann E; Prehn S; Rapoport TA; Dobberstein B
    EMBO J; 1999 Sep; 18(17):4804-15. PubMed ID: 10469658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.
    Sievers E; Neumann J; Raftery M; SchOnrich G; Eis-Hübinger AM; Koch N
    Immunology; 2002 Sep; 107(1):129-35. PubMed ID: 12225371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
    Powis SJ
    FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
    Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
    J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain.
    Ashman JB; Miller J
    J Immunol; 1999 Sep; 163(5):2704-12. PubMed ID: 10453012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules.
    Reber AJ; Turnquist HR; Thomas HJ; Lutz CT; Solheim JC
    Immunogenetics; 2002 May; 54(2):74-81. PubMed ID: 12037599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
    Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
    J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions.
    Buckner J; Kwok WW; Nepom B; Nepom GT
    J Immunol; 1996 Dec; 157(11):4940-5. PubMed ID: 8943399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.